OncoMatch/Clinical Trials/NCT07137793
Clinical Study to Evaluate The Cardioprotective Effect of Pentoxifylline Against Doxorubicin Induced Cardiotoxicity in Breast Cancer Patients
Is NCT07137793 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Pentoxifylline 400mg plus chemotherapy for doxorubicin induced cardiotoxicity.
Treatment: Pentoxifylline 400mg plus chemotherapy — The goal of this clinical trial is to evaluate the cardioprotective effect of pentoxifylline against doxorubicin-induced cardiotoxicity in breast cancer patients. The main questions it aims to answer are: 1. What is the change in ejection fraction (primary outcome) in breast cancer patients receiving pentoxifylline compared to those who do not? 2. What are the changes in serum levels of N-terminal pro-B-type natriuretic peptide (NT-pro-BNP), and TNF-α (secondary outcomes) in breast cancer patients receiving pentoxifylline compared to those who do not? Researcher will compare breast cancer patients receiving standard chemotherapy alone (Group one: Positive control group; n=23) to breast cancer patients receiving standard chemotherapy plus pentoxifylline (Group two: pentoxifylline group; n=23) to see if pentoxifylline mitigates the cardiac side effects associated with doxorubicin treatment. Participants will: Be randomized to receive either a chemotherapeutic regimen alone or with pentoxifylline.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Breast Carcinoma
Disease stage
Required: Stage I, II, III
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: doxorubicin (doxorubicin)
Formerly treated with DOX.
Lab requirements
Blood counts
absolute neutrophilic count ≥ 1.5 ×10^9/L, platelet count ≥ 90 × 10^9/L and hemoglobin level ≥ 10 g/dl
Kidney function
Creatine Clearance ≥ 50 mL/min
Liver function
adequate liver function
Cardiac function
Echocardiographic LVEF ≥55%. History of heart failure or LVEF <50% [excluded]. Presence of any cardiac-related conditions such as angina pectoris, valvular disease, uncontrolled systemic hypertension, coronary heart disease, and cardiac surgery within the last 3 months [excluded].
Echocardiographic LVEF ≥55%. Adequate baseline hematologic values (absolute neutrophilic count ≥ 1.5 ×10^9/L, platelet count ≥ 90 × 10^9/L and hemoglobin level ≥ 10 g/dl). Patients with adequate liver function and adequate renal function. Creatine Clearance < 50 mL/min [excluded]. History of heart failure or LVEF <50%. Presence of any cardiac-related conditions such as angina pectoris, valvular disease, uncontrolled systemic hypertension, coronary heart disease, and cardiac surgery within the last 3 months.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07137793 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage I or II or III is required.
Is there an age limit?
Yes. Patients must be 60 years or younger.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages